UNC alum, pharmaceutical exec Fred Eshelman makes another investment: experimental cancer treatment
Posted Apr 28, 2015
Fred Eshelman made another move by joining a group that invested $28 million in Innocrin Pharmaceuticals, a company developing treatments for breast and prostate cancers. Eshelman, who recently founded Eshelman Ventures, also joined Innocrin's board.
(Triangle Business Journal)
Related: Campus Connections
Meet the Carolina Class of 2025More than 6,800 Tar Heels, including undergrad, graduate and professional students, will have their Carolina degrees conferred at Spring Commencement on May 10. More than...
Thu May 1, 2025Carolina biologist wins Wolf Prize in Agriculture
Jeffery L. Dangl, a biologist at UNC-Chapel Hill, was part of an award-winning trio of researchers who received the 2025 Wolf Prize in Agriculture “for...
Tue Apr 29, 2025
Comedian, UNC alum Lewis Black returns to alma mater for final tour
Now 76, Lewis Black is embarking on “Goodbye Yeller Brick Road, The Final Tour.” Fittingly, the tour will bring Black back to the same town...
Sun Apr 27, 2025
Remembering Carl Boettcher, UNC carver and WWI emigre
Pieces of UNC’s history remain throughout campus, and some were created by a man who came to the United States for a better life. A...
Fri Apr 25, 2025